Table 3.
Summary of radiological responses in relation to seizure outcome
| Article | Treatment | Time of Response Assessment | Radiological Response, n | Related Seizure Outcome |
|---|---|---|---|---|
| Rogers et al, 199327 | Focal fractionated irradiation | N/S | 3/5 (60%) | Patients with medically intractable epilepsy: >75% seizure reduction in 3 patients with PR and in 1 patient with SD |
| Brada et al, 200336 | TMZ | Every 3 m in year 1, every 6 m in year 2–3; maximum response was assessed after a median of 12–15 m | 17/29 (59%) | Patients with history of epilepsy: seizure reduction in 10/15 (67%) with response on MRI and in 4/12 (33%) without a response on MRI |
| Pace et al, 200341 | TMZ | Every 3 treatment cycles with a median duration of response of 10 m | 24/43 (56%) | Patients with previously uncontrolled epilepsy: seizure reduction in 8/12 patients (67%) with CR or PR on MRI and in 7/14 patients (50%) with SD on MRI |
| Hoang-Xuan et al, 200438 | TMZ | After median follow-up of 14 m (range 6–46 m) | 18/59 (31%) | Neurological improvement (eg, a seizure reduction) in 12/36 (33%) with stable disease on MRI |
| Biemond-ter Stege et al, 200534 | PCV chemotherapy | N/S | 16/20 (80%) | Improved seizure control in most of 16 patients showing radiological response to treatment |
| Sherman et al, 201112 | TMZ | N/S | N/S | Seizure reduction in 1/23 patients with an MRI response. All other patients with a seizure reduction had SD on MRI |
| Ruda et al, 201313 | Focal fractionated irradiation | After 3 m After 6 m After 12 m |
18/43 (42%) 14/34 (41%) N/S |
Seizure reduction in 15/18 (83%) with response on MRI and 16/25 (64%) without a response on MRI Seizure reduction in 12/14 (86%) with response on MRI and 14/20 (70%) without a response on MRI Seizure reduction in 78% with response on MRI and 76% without a response on MRI |
| Koekkoek et al, 201440 | TMZ | After 6 m | 15/62 (24%) | Seizure reduction in 8/28 (29%) with response on MRI and in 7/34 (21%) without a response on MRI |
Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PCV, procarbazine, lomustine, and vincristine; N/S, not specified; m, months.